Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer

Kinoshita,Jun; Fushida,Sachio; Tsukada,Tomoya; Oyama,Katsunobu; Watanabe,Toshihumi; Shoji,Masatoshi; Okamoto,Koichi; Nakanuma,Shinichi; Sakai,Seisho; Makino,Isamu; Furukawa,Hiroyuki; Hayashi,Hironori; Nakamura,Keishi; Inokuchi,Masahumi; Nakagawara,Hisatoshi; Miyashita,Tomoharu; Tajima,Hidehiro; Takamura,Hiroyuki; Ninomiya,Itasu; Fujimura,Takashi; Masakazu,Yashiro; Hirakawa,Kosei; Ohta,Tetsuo

doi:10.3892/or.2014.3210

Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer

Authors:
- Jun Kinoshita
- Sachio Fushida
- Tomoya Tsukada
- Katsunobu Oyama
- Toshihumi Watanabe
- Masatoshi Shoji
- Koichi Okamoto
- Shinichi Nakanuma
- Seisho Sakai
- Isamu Makino
- Hiroyuki Furukawa
- Hironori Hayashi
- Keishi Nakamura
- Masahumi Inokuchi
- Hisatoshi Nakagawara
- Tomoharu Miyashita
- Hidehiro Tajima
- Hiroyuki Takamura
- Itasu Ninomiya
- Takashi Fujimura
- Yashiro Masakazu
- Kosei Hirakawa
- Tetsuo Ohta
View Affiliations

Affiliations: Department of Gastroenterologic Surgery, Division of Cancer Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8641, Japan, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585, Japan
Published online on: May 23, 2014 https://doi.org/10.3892/or.2014.3210
Pages: 89-96

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Intraperitoneal (i.p.) chemotherapy with paclitaxel (PTX) has been shown to be a promising treatment strategy for peritoneal metastasis. The present study focused on the comparative evaluation of the therapeutic efficacy of nanoparticle albumin-bound PTX (Nab-PTX) and i.p. administration of the conventional solvent-based PTX (Sb-PTX). We also investigated the difference in antitumor activity depending on the route of administration in the Nab-PTX treatment. Nab-PTX was administered i.p. or intravenously (i.v.) and Sb-PTX was administered i.p. at equitoxic and equal doses to nude mice bearing gastric cancer OCUM-2MD3 cell subcutaneous and peritoneal xenografts. Therapeutic efficacy of Sb-PTX and Nab-PTX was evaluated as inhibition of tumor growth using a peritoneal metastatic model with subcutaneous xenografts. The survival rate was also investigated using mouse peritoneal models. For assessment of subcutaneous tumors, the change in tumor volume was measured, and for assessment of peritoneal tumors, the weight of ascitic fluid and the total peritoneal tumor burden were measured for each individual mouse. At equitoxic doses, treatment with Nab-PTX resulted in a greater reduction in the size of subcutaneous tumors and the weight of ascites and peritoneal burden as compared with i.p. Sb-PTX (p<0.05). Treatment with i.p. and i.v. Nab-PTX also achieved greater survival benefit than i.p. Sb-PTX (p<0.05). In contrast, there was no significant difference in the degree of tumor reduction and the survival time between both drugs at equal doses. With regard to the route of administration, the antitumor efficacy of Nab-PTX after i.v. administration was equivalent to the efficacy after i.p. administration. These results suggest that i.v. Nab-PTX may be another encouraging treatment option that can target peritoneal dissemination in gastric cancer.

View Figures

View References

1	Siewert JR, Bottcher K, Roder JD, Busch R, Hermanek P and Meyer HJ: Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg. 80:1015–1018. 1993. View Article : Google Scholar : PubMed/NCBI
2	Allum WH, Powell DJ, McConkey CC and Fielding JW: Gastric cancer: a 25-year review. Br J Surg. 76:535–540. 1989.PubMed/NCBI
3	Rowinsky EK, Cazenave LA and Donehower RC: Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 82:1247–1259. 1990. View Article : Google Scholar : PubMed/NCBI
4	Carney DN: Chemotherapy in the management of patients with inoperable non-small cell lung cancer. Semin Oncol. 23:71–75. 1996.PubMed/NCBI
5	Crown J and O’Leary M: The taxanes: an update. Lancet. 355:1176–1178. 2000. View Article : Google Scholar : PubMed/NCBI
6	Gelmon K: The taxoids: paclitaxel and docetaxel. Lancet. 344:1267–1272. 1994. View Article : Google Scholar : PubMed/NCBI
7	Ohtsu A, Boku N, Tamura F, et al: An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol. 21:416–419. 1998. View Article : Google Scholar : PubMed/NCBI
8	Yamada Y, Shirao K, Ohtsu A, et al: Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol. 12:1133–1137. 2001. View Article : Google Scholar
9	Hironaka S, Zenda S, Boku N, et al: Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer. 9:14–18. 2006. View Article : Google Scholar : PubMed/NCBI
10	Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W and Markman M: Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol. 13:2961–2967. 1995.PubMed/NCBI
11	Markman M, Brady MF, Spirtos NM, Hanjani P and Rubin SC: Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol. 16:2620–2624. 1998.PubMed/NCBI
12	Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006. View Article : Google Scholar : PubMed/NCBI
13	Ishigami H, Kitayama J, Kaisaki S, et al: Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 21:67–70. 2010. View Article : Google Scholar : PubMed/NCBI
14	Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, Oyama K, Sudo Y, Watanabe Y and Fujimura T; Society for the Study of Peritoneal Carcinomatosis in Gastric Cancer. Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 71:1265–1272. 2013. View Article : Google Scholar : PubMed/NCBI
15	Fujiwara Y, Takiguchi S, Nakajima K, et al: Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol. 105:38–42. 2012. View Article : Google Scholar : PubMed/NCBI
16	Imano M, Yasuda A, Itoh T, et al: Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis. J Gastrointest Surg. 16:2190–2196. 2012. View Article : Google Scholar
17	Weiss RB, Donehower RC, Wiernik PH, et al: Hypersensitivity reactions from Taxol. J Clin Oncol. 8:1263–1268. 1990.PubMed/NCBI
18	Kloover JS, den Bakker MA, Gelderblom H and van Meerbeeck JP: Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer. 90:304–305. 2004. View Article : Google Scholar : PubMed/NCBI
19	ten Tije AJ, Verweij J, Loos WJ and Sparreboom A: Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 42:665–685. 2003.PubMed/NCBI
20	Sparreboom A, van Zuylen L, Brouwer E, et al: Cremophor EL- mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 59:1454–1457. 1999.
21	Gradishar WJ, Tjulandin S, Davidson N, et al: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 23:7794–7803. 2005. View Article : Google Scholar : PubMed/NCBI
22	Simionescu M, Gafencu A and Antohe F: Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey. Microsc Res Tech. 57:269–288. 2002. View Article : Google Scholar : PubMed/NCBI
23	John TA, Vogel SM, Tiruppathi C, Malik AB and Minshall RD: Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol. 284:L187–L196. 2003. View Article : Google Scholar : PubMed/NCBI
24	Desai N, Trieu V, Damascelli B and Soon-Shiong P: SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol. 2:59–64. 2009. View Article : Google Scholar : PubMed/NCBI
25	Von Hoff DD, Ramanathan RK, Borad MJ, et al: Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 29:4548–4554. 2011.
26	Socinski MA, Bondarenko I, Karaseva NA, et al: Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 30:2055–2062. 2012. View Article : Google Scholar : PubMed/NCBI
27	Takiuchi H, Sasaki Y, Nishina T, et al: ABI-007 in the treatment of unresectable or recurrent gastric cancer refractory to fluoropyrimidine-containing regimen: Updated data from the multicenter phase II study. J Clin Oncol (Meeting Abstracts). 30(Suppl 4): 902012.
28	Yashiro M, Chung YS, Nishimura S, Inoue T and Sowa M: Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Clin Exp Metastasis. 14:43–54. 1996. View Article : Google Scholar : PubMed/NCBI
29	Desai N, Trieu V, Yao Z, et al: Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 12:1317–1324. 2006. View Article : Google Scholar
30	Brouwer E, Verweij J, De Bruijn P, et al: Measurement of fraction unbound paclitaxel in human plasma. Drug Metab Dispos. 28:1141–1145. 2000.PubMed/NCBI
31	Kumar GN, Walle UK, Bhalla KN and Walle T: Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol. 80:337–344. 1993.PubMed/NCBI
32	Gardner ER, Dahut WL, Scripture CD, et al: Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res. 14:4200–4205. 2008. View Article : Google Scholar : PubMed/NCBI
33	Wang CS, Lin KH, Chen SL, Chan YF and Hsueh S: Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer. 91:1924–1930. 2004. View Article : Google Scholar : PubMed/NCBI
34	Zhao ZS, Wang YY, Chu YQ, Ye ZY and Tao HQ: SPARC is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 16:260–268. 2010. View Article : Google Scholar : PubMed/NCBI
35	Said N and Motamed K: Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol. 167:1739–1752. 2005. View Article : Google Scholar : PubMed/NCBI
36	Kamijo Y, Ito C, Sai Y and Miyamoto K: Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats. Cancer Lett. 287:182–186. 2010. View Article : Google Scholar : PubMed/NCBI
37	Matsumura Y and Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46:6387–6392. 1986.
38	Vicent MJ and Duncan R: Polymer conjugates: nanosized medicines for treating cancer (Review). Trends Biotechnol. 24:39–47. 2006. View Article : Google Scholar : PubMed/NCBI
39	Duncan R: Polymer conjugates as anticancer nanomedicines (Review). Nat Rev Cancer. 6:688–701. 2006. View Article : Google Scholar : PubMed/NCBI
40	Emoto S, Yamaguchi H, Kishikawa J, Yamashita H, Ishigami H and Kitayama J: Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination. Cancer Sci. 103:1304–1310. 2012. View Article : Google Scholar : PubMed/NCBI